Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-L1 Expression in Endometrial Cancer and Its Association with Clinicopathological Features: A Systematic Review and Meta-Analysis
Mohd Nazzary Mamat Yusof, Kah Teik Chew, Nirmala Chandralega Kampan, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3911-3911
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4564-4574
Open Access | Times Cited: 32
The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations
Angela Santoro, Giuseppe Angelico, Frediano Inzani, et al.
Gynecologic Oncology (2024) Vol. 184, pp. 57-66
Open Access | Times Cited: 13
Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis
Mohd Nazzary Mamat Yusof, Kah Teik Chew, Abdul Muzhill Hannaan Abdul Hafizz, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4032-4032
Open Access | Times Cited: 18
Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
Л. А. Таширева, Irina Larionova, N. A. Ermak, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
The Gut–Endometrium Axis: Exploring the Role of Microbiome in the Pathogenesis and Treatment of Endometrial Cancer—A Narrative Review
B.R. Zhang, Nur Fatin Nabilah Mohd Sahardi, Wen Di, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 1044-1044
Open Access
The role and participation of immune cells in the endometrial tumor microenvironment
Debasish Kumar Dey, Danielle Krause, Rajani Rai, et al.
Pharmacology & Therapeutics (2023) Vol. 251, pp. 108526-108526
Closed Access | Times Cited: 12
Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
Mohd Nazzary Mamat Yusof, Kah Teik Chew, Nirmala Chandralega Kampan, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15233-15233
Open Access | Times Cited: 12
Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis
Hanlin Fu, Zhihui Fu, Meng Mao, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 189, pp. 104084-104084
Open Access | Times Cited: 11
Gene expression and soluble protein level of PD-1 and its ligands (PD-L1 and PD-L2) in endometrial cancer
Mohd Nazzary Mamat Yusof, Kah Teik Chew, Nirmala Chandralega Kampan, et al.
PLoS ONE (2025) Vol. 20, Iss. 3, pp. e0312765-e0312765
Open Access
Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors
Alexandra Lainé, Andrea M. Gonzalez-Lopez, Uzma Hasan, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2042-2042
Open Access | Times Cited: 8
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer
Daniele Fanale, Chiara Brando, Lidia Rita Corsini, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer
Junhwan Kim, Se Ik Kim, Nae Ry Kim, et al.
Gynecologic Oncology (2023) Vol. 174, pp. 231-238
Closed Access | Times Cited: 8
Comprehensive Immunohistochemical Analysis of Mesonephric Marker Expression in Low-grade Endometrial Endometrioid Carcinoma
Yurimi Lee, Sangjoon Choi, Hyun Soo Kim
International Journal of Gynecological Pathology (2023)
Open Access | Times Cited: 5
Mesonephric-like Adenocarcinoma of the Uterine Corpus: Genomic and Immunohistochemical Profiling with Comprehensive Clinicopathological Analysis of 17 Consecutive Cases from a Single Institution
Hyun Hee Koh, Eunhyang Park, Hyun Soo Kim
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2269-2269
Open Access | Times Cited: 5
Clinical Implication of PD-L1 Expression in Patients with Endometrial Cancer
Yeorae Kim, Ala Aiob, Hyojin Kim, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2691-2691
Open Access | Times Cited: 5
Correlation between estrogen receptor and programmed death ligand-1 in type I endometrial cancer
Setyo Teguh Waluyo, Brahmana Askandar Tjokroprawiro, Anny Setijo Rahaju
European Journal of Obstetrics & Gynecology and Reproductive Biology X (2024) Vol. 21, pp. 100293-100293
Open Access | Times Cited: 1
Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment
Manel Albertí‐Valls, S. Muntión Olave, Anna Olomí, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 3918-3918
Open Access | Times Cited: 1
Heterogeneity of CD40 Expression in Different Types of High-Risk Endometrial Cancer Affects Discordant Prognostic Outcomes
Na Zhao, Bowen Sun, Yuan Cheng, et al.
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 549-556
Open Access | Times Cited: 3
Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis
Yemin Wang, Wei Cai, Qing-Ming Xue, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Radiogenomics for predicting microsatellite instability status and PD-L1 expression with machine learning in endometrial cancers: A multicenter study
Qianling Li, Yanan Huang, Xia Yang, et al.
Heliyon (2023) Vol. 9, Iss. 12, pp. e23166-e23166
Open Access | Times Cited: 2
Correlation of PD-L1 immunohistochemical expression with microsatellite instability and p53 status in endometrial carcinoma
Mohammad Arafa, Abdelhadi M. Shebl, Amany Salama, et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology X (2022) Vol. 16, pp. 100172-100172
Open Access | Times Cited: 3
Programmed Death Ligand 1: Unveiling its Impact on Endometrial Carcinogenesis
Antonios Koutras, Zacharias Fasoulakis, Vasiliki Mollaki, et al.
Cancer Diagnosis & Prognosis (2024) Vol. 4, Iss. 2, pp. 91-96
Open Access
Prognostic significance of the immune microenvironment in endometrial cancer
Miseon Lee, Wonkyung Jung, Jeong-Seok Kang, et al.
Laboratory Investigation (2024) Vol. 104, Iss. 9, pp. 102126-102126
Closed Access
PD-L1 Expression and Immune Infiltration Across Molecular Subtypes of Endometrial Cancer: An Integrative-Analysis of Molecular Classification and Immune Subtypes
Yanhui Zhang, Baohui Ju, Run-Fen Cheng, et al.
Human Pathology (2024) Vol. 154, pp. 105704-105704
Closed Access
A Transformer-based Semantic-Aware U-Net model for Improving Endometrial Cancer Detection
Karthick Natarajan
Deleted Journal (2024) Vol. 20, Iss. 3, pp. 6900-6911
Open Access
Page 1 - Next Page

Scroll to top